US Patent Issued to Novartis on Dec. 9 for "Methods of treating metabolic disorders with FGF21 variants" (Massachusetts Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,491,231, issued on Dec. 9, was assigned to Novartis AG (Basel, Switzerland).

"Methods of treating metabolic disorders with FGF21 variants" was invented by Allison Goldfine (Wayland, Mass.) and Byungdoo Alexander Yi (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are methods of treating, preventing, and managing metabolic or cardiovascular disorders and methods of reducing cardiovascular risk with FGF21 protein variants, including Fc-FGF21 variant fusion proteins."

The patent was filed on July 26, 2023, under Application No. 18/359,559.

*For further information, including images, charts and tables, please visit: http://p...